drugset / Trial / NCT05519514

Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

NCT05519514

Phase 1 Completed 56 enrolled Abbott
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open label, single dose, balanced, two treatment, two sequence, four period, fully replicate, cross over bioequivalence study under fasting condition.

Timeline

Start
2021-07-12
Primary completion
2021-08-08
Completion
2021-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 9 mg

Indications

No indication recorded.